Study Guides (299,514)
CA (140,975)
UOttawa (10,810)
PHA (30)
Study Guide

PHA3112- Midterm Exam Guide - Comprehensive Notes for the exam ( 22 pages long!)

22 pages126 viewsWinter 2017

Department
Pharmacology
Course Code
PHA 3112
Professor
Frank Feiner
Study Guide
Midterm

This preview shows pages 1-3. to view the full 22 pages of the document.
UOttawa
PHA3112
MIDTERM EXAM
STUDY GUIDE
You're Reading a Preview

Unlock to view full version

Only page 1 are available for preview. Some parts have been intentionally blurred.

You're Reading a Preview

Unlock to view full version

Only page 1 are available for preview. Some parts have been intentionally blurred.

Amantadine Duodopa, sinemet
Benzotropine Mirapex
Entacapone eldepryl
Levodopa and carbidopa Cogentin
Pramipexole comtan
Selegiline Symmetrel
Memantine
Rivastigmine
find more resources at oneclass.com
find more resources at oneclass.com
You're Reading a Preview

Unlock to view full version

Only page 1 are available for preview. Some parts have been intentionally blurred.

Parkinsons
1. We convert to DA in the brain. One of us blocks the destruction of the other, and we are a first
line drug. I’m used as a dopamine replacement.
2. I directly activate DA receptors, and I’m used as a first line drug supplement or to supplement
levodopa. I’m a dopamine agonist.
3. I inhibit the breakdown of levodopa by COMT, I’m safer than levodopa
4. I inhibit the breakdown of dopamine by MAO-8, I’m used for newly diagnosed patients and for
“off” times during levodopa therapy.
5. I promote the release of DA from remaining DA neurons: I may also block DA reuptake, AND
may help reduce levodopa induced dyskinesia.
6. I block muscarinic ACh receptors in the striatum, and I block PNS ACh receptors. I have many
side effects! Some include dry mouth, constipation, urinary retention, tachycardia, photophobia
and blurred vision. I have a safety alert to NOT use in elderly.
7. I directly activate DA receptors
8. Converts to DA in brain
9. Blocks muscarinic ACh receptors in striatum and PNS
10. Inhibit the breakdown of levodopa by COMT
11. Inhibits breakdown of DA by MAO-8
12. Promotes release of DA from remaining DA neurons.
13. What do the trials for pimavanserin indicate?
find more resources at oneclass.com
find more resources at oneclass.com
You're Reading a Preview

Unlock to view full version


Loved by over 2.2 million students

Over 90% improved by at least one letter grade.